公开(公告)号：US08212036B2

公开(公告)日：2012-07-03

申请号：US12498769

申请日：2009-07-07

Applicant: H. Scott Wilkinson ,  Richard Hsia ,  Tushar Misra ,  Kostas Saranteas

Inventor： H. Scott Wilkinson ,  Richard Hsia ,  Tushar Misra ,  Kostas Saranteas

IPC: C07D471/00

CPC classification number: C07D487/04 ,  C07C57/145

Abstract: Maleate salts of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are provided.

Abstract translation: （6-（5-氯-2-吡啶基）-5 - [（4-甲基-1-哌嗪基）羰氧基] -7-氧代-6,7-二氢-5H-吡咯并[3,4-b ]吡嗪）。

公开(公告)号：US08198278B2

公开(公告)日：2012-06-12

申请号：US12338903

申请日：2008-12-18

Applicant: Richard Hsia ,  H. Scott Wilkinson ,  Tushar Misra ,  Kostas Saranteas ,  Patrick Mousaw

Inventor： Richard Hsia ,  H. Scott Wilkinson ,  Tushar Misra ,  Kostas Saranteas ,  Patrick Mousaw

IPC: A61K31/495 ,  A61K31/4965

CPC classification number: C07D487/04

Abstract: Besylate salts of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl) carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are provided.

Abstract translation: （6-（5-氯-2-吡啶基）-5 - [（4-甲基-1-哌嗪基）羰氧基] -7-氧代-6,7-二氢-5H-吡咯并[3,4-b ]吡嗪）。

公开(公告)号：US20120136065A1

公开(公告)日：2012-05-31

申请号：US13365565

申请日：2012-02-03

Applicant: Thomas P. JERUSSI ,  Qun Kevin FANG ,  Mark G. CURRIE

Inventor： Thomas P. JERUSSI ,  Qun Kevin FANG ,  Mark G. CURRIE

IPC: A61K31/135 ,  A61P25/28

CPC classification number: A61K31/135 ,  C07B2200/07 ,  C07C211/42 ,  C07C2602/10

Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

Abstract translation: 用（1R，4S） - 反式-4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺处理CNS障碍; 和（1S，4R） - 反式-4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺。 还公开了制备4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺的方法。 该方法包括制备N- [4-（3,4-二氯苯基）-1,2,3,4-四氢萘-1-基]甲酰胺的全部四种异构体，它们也是有用的。

公开(公告)号：US20120077818A1

公开(公告)日：2012-03-29

申请号：US13320246

申请日：2010-05-12

Applicant: Una Campbell ,  Judith Dunn

Inventor： Una Campbell ,  Judith Dunn

IPC: A61K31/135 ,  A61K31/496 ,  A61P25/00 ,  A61P3/04 ,  A61P25/18 ,  A61P25/22 ,  A61P25/30 ,  A61K31/404 ,  A61P25/24

CPC classification number: A61K45/06 ,  A61K31/135 ,  A61K31/44 ,  A61K31/496 ,  A61K31/505 ,  A61K31/535 ,  A61K2300/00

Abstract: Provided herein are methods of and compositions for, treating, preventing and managing various neurological disorders. The methods comprise administering a transnorsertraline in combination with a serotonin receptor IA agonist, antagonist or modulator.

Abstract translation: 本文提供了用于，治疗，预防和控制各种神经障碍的方法和组合物。 所述方法包括与血清素受体IA激动剂，拮抗剂或调节剂组合施用跨氯三嗪。

公开(公告)号：US20240190835A1

公开(公告)日：2024-06-13

申请号：US18554071

申请日：2022-04-07

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Kevin Julian HODGETTS ,  Linghong XIE

IPC: C07D313/08 ,  A61K31/343 ,  A61K31/352 ,  C07D307/87 ,  C07D311/76

CPC classification number: C07D313/08 ,  A61K31/343 ,  A61K31/352 ,  C07D307/87 ,  C07D311/76

Abstract: Disclosed are isochromane and related compounds, and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

公开(公告)号：US20240150330A1

公开(公告)日：2024-05-09

申请号：US18554214

申请日：2022-04-06

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Dario DOLLER ,  Hongbing HUANG ,  Linghong XIE

IPC: C07D405/04 ,  C07D311/04 ,  C07D413/04 ,  C07D417/04

CPC classification number: C07D405/04 ,  C07D311/04 ,  C07D413/04 ,  C07D417/04

Abstract: Provided herein are compounds, pharmaceutical compositions, and methods of use thereof, including methods of treating a neurological or psychiatric disease or disorder. For example, provided herein is a compound of Formula I:




or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., Ring A, X1, R1, R2, R3, R4, and R5) are as disclosed herein. The compounds disclosed herein (e.g., compounds of Formula I, or pharmaceutically acceptable salts thereof) and pharmaceutical compositions can be used to treat a neurological or psychiatric disease or disorder.

公开(公告)号：US20230241024A1

公开(公告)日：2023-08-03

申请号：US17933881

申请日：2022-09-21

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Linda Jane BRISTOW ,  Nina DEDIC ,  Eva HAJOS-KORCSOK ,  Seth Cabot HOPKINS ,  Philip Glyn JONES ,  Kenneth S. KOBLAN ,  Snezana MILANOVIC ,  Colleen Marie SYNAN ,  Kuangnan XIONG

IPC: A61K31/381 ,  A61P3/04 ,  A61P3/10 ,  A61P25/18 ,  A61K31/5513

CPC classification number: A61K31/381 ,  A61K31/5513 ,  A61P3/04 ,  A61P3/10 ,  A61P25/18

Abstract: Provided herein are compounds, pharmaceutical compositions, and methods of use thereof, including methods of treating metabolic disorders and psychiatric disorders and diseases associated with metabolic disorders. For example, provided herein is Compound 1:





or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions and methods of use thereof, including methods of treating metabolic disorders and psychiatric disorders associated with metabolic disorders.

公开(公告)号：US11654113B2

公开(公告)日：2023-05-23

申请号：US17490616

申请日：2021-09-30

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Takumi Asada ,  Gerald R. Galluppi ,  Seth Cabot Hopkins ,  Megumi Maruyama ,  Siriporn Toongsuwan ,  Yuki Tsushima

IPC: A61K9/20 ,  A61K31/40 ,  A61K47/38 ,  A61P25/18 ,  A61P25/24

CPC classification number: A61K9/2054 ,  A61K31/40 ,  A61K47/38 ,  A61P25/18 ,  A61P25/24

Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.

公开(公告)号：US20220402937A1

公开(公告)日：2022-12-22

申请号：US17814378

申请日：2022-07-22

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Andrea BAUER ,  Nandkumar Nivritti BHOGLE ,  Xiaoxia CHEN ,  Shahla JAMZAD ,  Robert Joseph PRYTKO ,  Kostas SARANTEAS ,  Michael Joseph SIZENSKY ,  Harold Scott WILKINSON ,  Haitao ZHANG

IPC: C07D495/04 ,  A61P25/18 ,  A61K9/20 ,  A61K45/06 ,  A61K31/381 ,  A61P25/00

Abstract: Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.

公开(公告)号：US11491133B2

公开(公告)日：2022-11-08

申请号：US16991771

申请日：2020-08-12

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Carrie A. Bowen ,  Douglas F. Burdi ,  Michele L. R. Heffernan ,  Lee W. Herman ,  Linghong Xie

IPC: A61K31/352 ,  A61P25/28 ,  A61P25/24 ,  A61P25/08 ,  A61P25/16 ,  C07D413/04 ,  C07D417/04 ,  C07D405/04 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/42 ,  A61K31/427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/497 ,  A61K31/506

Abstract: Compounds of Formula I are described as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need are also disclosed.